JP2022543679A5 - - Google Patents

Info

Publication number
JP2022543679A5
JP2022543679A5 JP2022507799A JP2022507799A JP2022543679A5 JP 2022543679 A5 JP2022543679 A5 JP 2022543679A5 JP 2022507799 A JP2022507799 A JP 2022507799A JP 2022507799 A JP2022507799 A JP 2022507799A JP 2022543679 A5 JP2022543679 A5 JP 2022543679A5
Authority
JP
Japan
Prior art keywords
pharmaceutically acceptable
acceptable salt
approximately
free base
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022507799A
Other languages
English (en)
Japanese (ja)
Other versions
JP7526783B2 (ja
JP2022543679A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/045410 external-priority patent/WO2021026454A1/en
Publication of JP2022543679A publication Critical patent/JP2022543679A/ja
Publication of JP2022543679A5 publication Critical patent/JP2022543679A5/ja
Application granted granted Critical
Publication of JP7526783B2 publication Critical patent/JP7526783B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022507799A 2019-08-08 2020-08-07 癌を処置する方法 Active JP7526783B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CNPCT/CN2019/099754 2019-08-08
CN2019099754 2019-08-08
PCT/US2020/045410 WO2021026454A1 (en) 2019-08-08 2020-08-07 Method of treating cancer

Publications (3)

Publication Number Publication Date
JP2022543679A JP2022543679A (ja) 2022-10-13
JP2022543679A5 true JP2022543679A5 (enExample) 2023-08-10
JP7526783B2 JP7526783B2 (ja) 2024-08-01

Family

ID=72234946

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022507799A Active JP7526783B2 (ja) 2019-08-08 2020-08-07 癌を処置する方法

Country Status (12)

Country Link
US (2) US20210038578A1 (enExample)
EP (1) EP4009969A1 (enExample)
JP (1) JP7526783B2 (enExample)
KR (1) KR20220047589A (enExample)
CN (1) CN114080225A (enExample)
AU (1) AU2020327022B2 (enExample)
BR (1) BR112022001508A2 (enExample)
CA (1) CA3148115A1 (enExample)
IL (1) IL289811A (enExample)
MX (1) MX2022001450A (enExample)
TW (1) TWI857119B (enExample)
WO (1) WO2021026454A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7010330B1 (en) 2003-03-01 2006-03-07 Theta Microelectronics, Inc. Power dissipation reduction in wireless transceivers
EP4438046A4 (en) * 2021-11-27 2025-12-03 Transthera Sciences Nanjing Inc NEW APPLICATION OF KINASE INHIBITOR
US20250177352A1 (en) 2022-03-14 2025-06-05 Laekna Limited Combination treatment for cancer

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2601675B1 (fr) 1986-07-17 1988-09-23 Rhone Poulenc Sante Derives du taxol, leur preparation et les compositions pharmaceutiques qui les contiennent
ES2138618T3 (es) 1992-03-31 2000-01-16 Btg Int Ltd Esteroides 17-sustituidos utiles en el tratamiento del cancer.
MA23823A1 (fr) 1995-03-27 1996-10-01 Aventis Pharma Sa Nouveaux taxoides, leur preparation et les compositions qui les contiennent
EP1294358B1 (en) 2000-06-28 2004-08-18 Smithkline Beecham Plc Wet milling process
US7709517B2 (en) 2005-05-13 2010-05-04 The Regents Of The University Of California Diarylhydantoin compounds
BRPI0709771B1 (pt) 2006-03-27 2022-01-25 The Regents Of The University Of California Composto e composição farmacêutica
UY30892A1 (es) 2007-02-07 2008-09-02 Smithkline Beckman Corp Inhibidores de la actividad akt
NZ594064A (en) * 2009-01-30 2012-08-31 Glaxosmithkline Llc Crystalline n-{ (1s)-2-amino-1-[(3-fluorophenyl)methyl]ethyl} -5-chloro-4-(4-chloro-1-methyl-1h-pyrazol-5-yl)-2-thiophenecarboxamide hydrochloride
PE20121048A1 (es) * 2009-06-26 2012-08-25 Novartis Ag Derivados de imidazolidin-2-ona 1,3-disustituida como inhibidores de cyp17
AR078793A1 (es) 2009-10-27 2011-12-07 Orion Corp Derivados de carboxamidas no esteroidales y acil hidrazona moduladores de receptores androgenicos de tejido selectivo (sarm), composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento del cancer de prostata entre otros
CA2872541A1 (en) * 2012-06-06 2013-12-12 Novartis Ag Combination of a 17 -alpha -hydroxylase (c17, 20 - lyase) inhibitor and a specific pi-3k inhibitor for treating a tumor disease
MX2016004267A (es) * 2013-10-01 2016-07-08 Novartis Ag Combinacion.
CN108112235A (zh) * 2015-03-06 2018-06-01 克利夫兰临床基金会 改变类固醇代谢以用于治疗类固醇依赖性疾病

Similar Documents

Publication Publication Date Title
CN103945849B (zh) 癌症的联合治疗
CN102770131A (zh) 卡巴他赛的新颖抗肿瘤用途
JP2019529574A5 (enExample)
TW202333675A (zh) 用於治療癌症之組合療法之用途
JP2024510666A5 (enExample)
WO2015185011A1 (zh) 喹啉衍生物用于治疗甲状腺癌的方法和用途以及用于治疗甲状腺癌的药物组合物
JP5514123B2 (ja) 卵巣癌を治療するための、パクリタキセルを含む配合剤
JP2023522415A5 (enExample)
JP2024102045A5 (enExample)
JP2023175688A5 (enExample)
JP2004525143A5 (enExample)
JP2025511402A5 (enExample)
JP2025511401A5 (enExample)
CN114903902A (zh) GnRH受体拮抗剂联合雄激素受体拮抗剂在制备治疗前列腺癌药物中的用途
JP2024506385A5 (enExample)
CN104968340A (zh) 治疗肝脏疾病或病状的用途和方法
JP2022524819A (ja) カプシド集合調節剤固体製剤
JP2025511403A5 (enExample)
WO2021034335A1 (en) Methods of administering tesetaxel with glucocorticoids that are cyp3a4 inducers
WO2019174590A1 (zh) 用于治疗三阴性乳腺癌的喹啉衍生物
JP2024506347A5 (enExample)
JP2019001830A (ja) 医薬
TW200902028A (en) Combination of progesterone-receptor antagonist together with an aromatase inhibitor for use in BRCA mediated diseases
TW201944997A (zh) 西達本胺與依西美坦在製備用於治療乳腺癌的聯合用藥物中的用途及聯合用藥物
WO2020205608A1 (en) Uses of androgen receptor antagonists and jnk pathway inhibitors, and pharmaceutical compositions related thereto